A study comparing 118 patients with fibromyalgia found an improvement of 36.5% in the amitriptyline group, 26.6% in the nortriptyline group, and 24% in the placebo group
Tirzepatide takes a dual-approach to weight management, offering powerful appetite control along with enhanced metabolic benefits
Tirzepatide typically starts at a lower absolute dose (2.5 mg) even if you were on a higher Ozempic dose, because tirzepatide's dual-receptor mechanism is more potent
On the other hand, its pretty clear that once patients stop taking these GLP-1 drugs, the likelihood is that theyre going to regain weight as their metabolism normalizes and they start to consume more calories
A Certificate of Analysis is available for every lot, issued per-lot by an independent laboratory and linked to the specific batch received
All peptide GLP-1 agonists were developed as subcutaneous injections because peptides face three fundamental barriers to oral bioavailability